ArticleEuropean journal of nuclear medicine and molecular imaging2022
GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 79 citations in OpenAlex.
- Head-to-head study of [BMC cancer · 2024Trial
- Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.EJNMMI research · 2026Review
- Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.European journal of nuclear medicine and molecular imaging · 2026Article
- HBx Induces the Production of N-GPC3 in Hepatoma Cells to Promote the Evasion of Macrophage Phagocytosis Through Activating Furin.Journal of cellular and molecular medicine · 2026Article
- US Molecular Imaging of Glypican-3 Expression in Hepatocellular Carcinoma Using Targeted Biosynthetic Gas Vesicles.Radiology. Imaging cancer · 2026Article
- Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3-Targeted Single-Domain Antibody PET.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Review
- Integrating GPC3 with Other Biomarkers to Improve the Diagnosis of Early-Stage Liver Cancer.Pathogens (Basel, Switzerland) · 2025Article
- Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.Cancer communications (London, England) · 2025Review
- In Vitro Characterization of the Published Glypican-3-Targeting Peptide TJ12P2 Reveals a Lack of Specificity and Potency.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Preclinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.Journal of clinical and translational hepatology · 2025Review
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
- Interplay of GPC3, Hsa-miR-135b-3p, and FTLP3 in lung cancer metastasis.Clinical & experimental metastasis · 2025Article
- Development and Characterization of the [Molecular pharmaceutics · 2025Article
- Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates.Nature communications · 2025Article
- Albumin-conjugation enables improved tumor targeting of aptamers via SPECT imaging.Molecular therapy. Nucleic acids · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEarly detection of hepatocellular carcinoma (HCC) remains a clinical challenge. Glypican 3 (GPC3) is a proteoglycan highly specific for HCC and is a potential diagnostic and therapeutic target for HCC. This work aims to develop GPC3-targeted immuno-positron emission tomography (immunoPET) imaging strategies and to assess the diagnostic values in preclinical HCC models.
methodsFlow cytometry was used to screen GPC3-positive HCC cell lines. The expression of GPC3 in HCCs was detected by immunohistochemistry on tissue microarray. A novel GPC3-specific single domain antibody (sdAb) was produced and labeled with gallium-68 (
resultsGPC3 was strongly expressed on HCC cell lines and patients with poorly differentiated HCC. [
conclusionsIn the work, we successfully developed sdAb-derived GPC3-targeted immunoPET imaging strategies and characterized the superior diagnostic accuracies in preclinical HCC models. Furthermore, we synthesized a fusion protein ABDG2 with improved targeting and pharmacokinetic properties, serving as a promising candidate for developing radioimmunotherapy agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.